Erik De Clercq

InstitutionRega Institute for Medical Research
vCardDownload vCard
    Publication Timeline
    COVID-19 publications
    Bar chart showing 5 Covid-19 publications, with a maximum of 1 publications in March 2020 and June 2020 and Spetember 2020 and December 2020 and April 2021
    All Publications
    Bar chart showing 676 publications over 21 distinct years, with a maximum of 66 publications in 2003
    These graphs show COVID-19 publications by month since August 2019 and all publications written by authors of COVID-19 publications over the past 30 years.

    To see the data from both graphs as text, click here.
    Publication Field Summary
    This graph shows the number and percent of publications by field. Fields are based on how the National Library of Medicine (NLM) classifies the publications' journals and might not represent the specific topics of the publications. Note that an individual publication can be assigned to more than one field. As a result, the publication counts in this graph might add up to more than the number of publications the person has written. To see the data as text, click here.
    Publication List
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications.
    Sort By:     Newest   |   Oldest   |   Most Cited   |   Most Discussed
    PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Miao M, Clercq E, Li G. Genetic Diversity of SARS-CoV-2 over a One-Year Period of the COVID-19 Pandemic: A Global Perspective. Biomedicines. 2021 Apr 11; 9(4). PMID: 33920487.
    2. Li G, Liu Y, Jing X, Wang Y, Miao M, Tao L, Zhou Z, Xie Y, Huang Y, Lei J, Gong G, Jin P, Hao Y, Faria NR, Clercq E, Zhang M. Mortality risk of COVID-19 in elderly males with comorbidities: a multi-country study. Aging (Albany NY). 2020 12 31; 13(1):27-60. PMID: 33472167.
      Citations: 4     Fields:    Translation:Humans
    3. Jiang C, Wang Y, Hu M, Wen L, Wen C, Wang Y, Zhu W, Tai S, Jiang Z, Xiao K, Faria NR, De Clercq E, Xu J, Li G. Antibody seroconversion in asymptomatic and symptomatic patients infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Clin Transl Immunology. 2020; 9(9):e1182. PMID: 33005417.
    4. Zhou Z, Zhang M, Wang Y, Zheng F, Huang Y, Huang K, Yu Q, Cai C, Chen D, Tian Y, Lei J, Xiao X, Clercq E, Li G, Xie Y, Gong G. Clinical characteristics of older and younger patients infected with SARS-CoV-2. Aging (Albany NY). 2020 06 22; 12(12):11296-11305. PMID: 32575073.
      Citations: 5     Fields:    Translation:HumansCellsPHPublic Health
    5. Li G, De Clercq E. Therapeutic options for the 2019 novel coronavirus (2019-nCoV). Nat Rev Drug Discov. 2020 03; 19(3):149-150. PMID: 32127666.
      Citations: 514     Fields:    Translation:HumansCells
    6. Shahar Yar M, Mustaqeem Abdullah M, Husain A, Bhakht MA, De Clercq E. Synthesis and evaluation of in vitro antiviral activity of 2-[3-(substituted phenyl)-4,5-dihydro-1H-5-pyrazolyl]benzofuran-3-yl chloride derivatives. J Enzyme Inhib Med Chem. 2009 Aug; 24(4):949-56. PMID: 19555169.
      Citations:    Fields:    Translation:HumansAnimalsCells
    7. Biot C, Daher W, Chavain N, Fandeur T, Khalife J, Dive D, De Clercq E. Design and synthesis of hydroxyferroquine derivatives with antimalarial and antiviral activities. J Med Chem. 2006 May 04; 49(9):2845-9. PMID: 16640347.
      Citations: 97     Fields:    Translation:AnimalsCells
    8. Balzarini J, Keyaerts E, Vijgen L, Egberink H, De Clercq E, Van Ranst M, Printsevskaya SS, Olsufyeva EN, Solovieva SE, Preobrazhenskaya MN. Inhibition of feline (FIPV) and human (SARS) coronavirus by semisynthetic derivatives of glycopeptide antibiotics. Antiviral Res. 2006 Oct; 72(1):20-33. PMID: 16675038.
      Citations: 26     Fields:    Translation:HumansAnimalsCells
    9. De Clercq E. Potential antivirals and antiviral strategies against SARS coronavirus infections. Expert Rev Anti Infect Ther. 2006 Apr; 4(2):291-302. PMID: 16597209.
      Citations: 56     Fields:    Translation:HumansAnimalsCells
    10. Balzarini J, Keyaerts E, Vijgen L, Vandermeer F, Stevens M, De Clercq E, Egberink H, Van Ranst M. Pyridine N-oxide derivatives are inhibitory to the human SARS and feline infectious peritonitis coronavirus in cell culture. J Antimicrob Chemother. 2006 Mar; 57(3):472-81. PMID: 16387746.
      Citations: 16     Fields:    Translation:HumansAnimalsCells
    11. De Clercq E. Recent highlights in the development of new antiviral drugs. Curr Opin Microbiol. 2005 Oct; 8(5):552-60. PMID: 16125443.
      Citations: 23     Fields:    Translation:HumansAnimalsCells
    12. De Clercq E. Antivirals and antiviral strategies. Nat Rev Microbiol. 2004 Sep; 2(9):704-20. PMID: 15372081.
      Citations: 86     Fields:    Translation:HumansCells
    De Clercq's Networks
    Click the
    buttons for more information and interactive visualizations!
    Concepts (1138)
    Co-Authors (293)
    Similar People (60)
    Physical Neighbors